{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:09Z","timestamp":1790166189489,"version":"4.1.0"},"reference-count":57,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.3892\/or.2012.2153","type":"journal-article","created":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T07:41:19Z","timestamp":1354088479000},"page":"741-750","source":"Crossref","is-referenced-by-count":31,"title":["Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib"],"prefix":"10.3892","volume":"29","author":[{"given":"MARTA","family":"GROMICHO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARTA","family":"MAGALH\u00c3ES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00c1TIMA","family":"TORRES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOANA","family":"DINIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXANDRA R.","family":"FERNANDES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAULA","family":"RENDEIRO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PURIFICA\u00c7\u00c3O","family":"TAVARES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANT\u00d3NIO","family":"LAIRES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOS\u00c9","family":"RUEFF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANT\u00d3NIO SEBASTI\u00c3O","family":"RODRIGUES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2012,12,28]]},"reference":[{"key":"key20180107214519_b1-or-29-02-0741","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"key20180107214519_b2-or-29-02-0741","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"key20180107214519_b3-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"key20180107214519_b4-or-29-02-0741","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107214519_b5-or-29-02-0741","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"key20180107214519_b6-or-29-02-0741","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20180107214519_b7-or-29-02-0741","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107214519_b8-or-29-02-0741","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"key20180107214519_b9-or-29-02-0741","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"key20180107214519_b10-or-29-02-0741","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"key20180107214519_b11-or-29-02-0741","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"key20180107214519_b12-or-29-02-0741","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/10428190701858823","article-title":"Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia","volume":"49","author":"Clark","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180107214519_b13-or-29-02-0741","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"key20180107214519_b14-or-29-02-0741","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/138920112799857549","article-title":"Genomics and cancer drug resistance","volume":"13","author":"Rodrigues","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"key20180107214519_b15-or-29-02-0741","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/pbc.22220","article-title":"mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death","volume":"53","author":"Cortez","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"key20180107214519_b16-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.leu.2404859","article-title":"ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia","volume":"21","author":"Raaijmakers","year":"2007","journal-title":"Leukemia"},{"key":"key20180107214519_b17-or-29-02-0741","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/138945006778019345","article-title":"Cellular functions of vaults and their involvement in multidrug resistance","volume":"7","author":"Steiner","year":"2006","journal-title":"Curr Drug Targets"},{"key":"key20180107214519_b18-or-29-02-0741","first-page":"158","article-title":"Variation of MDR protein expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"key20180107214519_b19-or-29-02-0741","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of p-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry (Mosc)"},{"key":"key20180107214519_b20-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","article-title":"Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","volume":"52","author":"Gromicho","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"key20180107214519_b21-or-29-02-0741","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","article-title":"Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors","volume":"37","author":"Nijmeijer","year":"2009","journal-title":"Exp Hematol"},{"key":"key20180107214519_b22-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"key20180107214519_b23-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"key20180107214519_b24-or-29-02-0741","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00109-006-0097-6","article-title":"Quantitative real-time RT-PCR data analysis: current concepts and the novel \u2018gene expression\u2019s CT difference\u2019 formula","volume":"84","author":"Schefe","year":"2006","journal-title":"J Mol Med"},{"key":"key20180107214519_b25-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"key20180107214519_b26-or-29-02-0741","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol Therapy"},{"key":"key20180107214519_b27-or-29-02-0741","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4161\/cbt.7.3.5412","article-title":"Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib","volume":"7","author":"Gardner","year":"2008","journal-title":"Cancer Biol Therapy"},{"key":"key20180107214519_b28-or-29-02-0741","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin Pharm Ther"},{"key":"key20180107214519_b29-or-29-02-0741","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02977789","article-title":"Induction of phase I, II and III drug metabolism\/transport by xenobiotics","volume":"28","author":"Xu","year":"2005","journal-title":"Arch Pharm Res"},{"key":"key20180107214519_b30-or-29-02-0741","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107214519_b31-or-29-02-0741","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"key20180107214519_b32-or-29-02-0741","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.leu.2404131","article-title":"Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells","volume":"20","author":"de Grouw","year":"2006","journal-title":"Leukemia"},{"key":"key20180107214519_b33-or-29-02-0741","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.leukres.2009.09.026","article-title":"A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia","volume":"34","author":"de Lavallade","year":"2010","journal-title":"Leukemia Res"},{"key":"key20180107214519_b34-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach","volume":"20","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"key":"key20180107214519_b35-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood-2002-05-1366","article-title":"High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML","volume":"101","author":"Lange","year":"2003","journal-title":"Blood"},{"key":"key20180107214519_b36-or-29-02-0741","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4149\/neo_2009_03_202","article-title":"Imatinib is a substrate for various multidrug resistance proteins","volume":"56","author":"Czyzewski","year":"2009","journal-title":"Neoplasma"},{"key":"key20180107214519_b37-or-29-02-0741","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"},{"key":"key20180107214519_b38-or-29-02-0741","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001622-200011000-00007","article-title":"Lung resistance-related protein\/major vault protein and vaults in multidrug-resistant cancer","volume":"12","author":"Scheffer","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"key20180107214519_b39-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107214519_b40-or-29-02-0741","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","article-title":"Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity","volume":"24","author":"Engler","year":"2010","journal-title":"Leukemia"},{"key":"key20180107214519_b41-or-29-02-0741","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107214519_b42-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"key20180107214519_b43-or-29-02-0741","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107214519_b44-or-29-02-0741","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"key20180107214519_b45-or-29-02-0741","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12032-010-9781-z","article-title":"BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?","volume":"29","author":"Gruber","year":"2012","journal-title":"Med Oncol"},{"key":"key20180107214519_b46-or-29-02-0741","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"key20180107214519_b47-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"key20180107214519_b48-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"key20180107214519_b49-or-29-02-0741","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1182\/blood-2009-11-252155","article-title":"Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"key":"key20180107214519_b50-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"key20180107214519_b51-or-29-02-0741","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","volume":"89","author":"Sharma","year":"2010","journal-title":"Ann Hematol"},{"key":"key20180107214519_b52-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr\/Abl fusion transcripts","volume":"7","author":"Polampalli","year":"2008","journal-title":"Genetics Mol Res"},{"key":"key20180107214519_b53-or-29-02-0741","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"key20180107214519_b54-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"key20180107214519_b55-or-29-02-0741","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"key20180107214519_b56-or-29-02-0741","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med Oncol"},{"key":"key20180107214519_b57-or-29-02-0741","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2012.2153\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:45:36Z","timestamp":1515361536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2012.2153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,28]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,12,28]]},"published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.3892\/or.2012.2153"],"URL":"https:\/\/doi.org\/10.3892\/or.2012.2153","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,28]]}}}